GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Iterum Therapeutics PLC (NAS:ITRM) » Definitions » Price-to-Tangible-Book

Iterum Therapeutics (Iterum Therapeutics) Price-to-Tangible-Book : (As of May. 23, 2024)


View and export this data going back to 2018. Start your Free Trial

What is Iterum Therapeutics Price-to-Tangible-Book?

As of today (2024-05-23), Iterum Therapeutics's share price is $1.42. Iterum Therapeutics's Tangible Book per Share of Mar. 2024 for the quarter that ended in Mar. 2024 was $-0.37. Hence, Iterum Therapeutics's Price to Tangible Book Ratio of today is .

The historical rank and industry rank for Iterum Therapeutics's Price-to-Tangible-Book or its related term are showing as below:

During the past 8 years, Iterum Therapeutics's highest Price to Tangible Book Ratio was 8.94. The lowest was 0.40. And the median was 1.48.

ITRM's Price-to-Tangible-Book is not ranked *
in the Biotechnology industry.
Industry Median: 2.835
* Ranked among companies with meaningful Price-to-Tangible-Book only.

A closely related ratio is called PB Ratio. As of today, Iterum Therapeutics's share price is $1.42. Iterum Therapeutics's Book Value per Sharefor the quarter that ended in Mar. 2024 was $-0.37. Hence, Iterum Therapeutics's P/B Ratio of today is .


Iterum Therapeutics Price-to-Tangible-Book Historical Data

The historical data trend for Iterum Therapeutics's Price-to-Tangible-Book can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Iterum Therapeutics Price-to-Tangible-Book Chart

Iterum Therapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Price-to-Tangible-Book
Get a 7-Day Free Trial - - 1.53 0.40 -

Iterum Therapeutics Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Price-to-Tangible-Book Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.72 2.22 3.48 - -

Competitive Comparison of Iterum Therapeutics's Price-to-Tangible-Book

For the Biotechnology subindustry, Iterum Therapeutics's Price-to-Tangible-Book, along with its competitors' market caps and Price-to-Tangible-Book data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Iterum Therapeutics's Price-to-Tangible-Book Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Iterum Therapeutics's Price-to-Tangible-Book distribution charts can be found below:

* The bar in red indicates where Iterum Therapeutics's Price-to-Tangible-Book falls into.



Iterum Therapeutics Price-to-Tangible-Book Calculation

Iterum Therapeutics's price-to-tangible-book ratio for today is calculated as:

Price to Tangible Book=Share Price/Tangible Book per Share (Q: Mar. 2024 )
=1.42/-0.373
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

A closely related ratio is called PB Ratio. The difference between Price-to-Tangible-Book Ratio and PB Ratio is that book value other than intangibles are used in the calculation.


Be Aware

Some businesses have very light assets, such as software companies or insurance agencies. The Price-to-Book Ratio does not work well for these companies. Some companies even have negative equity, so the Price-to-Book Ratio cannot be applied to them.


Iterum Therapeutics Price-to-Tangible-Book Related Terms

Thank you for viewing the detailed overview of Iterum Therapeutics's Price-to-Tangible-Book provided by GuruFocus.com. Please click on the following links to see related term pages.


Iterum Therapeutics (Iterum Therapeutics) Business Description

Traded in Other Exchanges
N/A
Address
Fitzwilliam Court, 1st Floor, Leeson Close, Dublin, IRL, 2
Iterum Therapeutics PLC is a clinical-stage pharmaceutical company. The company is engaged in developing and commercializing sulopenem to be the first and only oral and intravenous branded penem available globally. Its sulopenem program has the potential to offer a solution to the problem of antibiotic resistance and the toxicity limitations of existing agents. The company operates as a single business segment, which is the development and commercialization of innovative treatments for drug-resistant bacterial infections.
Executives
Michael W. Dunne officer: Chief Scientific Officer DURATA THERAPEUTICS, INC., 89 HEADQUARTERS PLAZA NORTH, 14TH FLOOR, MORRISTOWN NJ 07960
Fishman Corey N. director, officer: President & CEO DURATA THERAPEUTICS, INC., 89 HEADQUARTERS PLAZA NORTH, 14TH FLOOR, MORRISTOWN NJ 07960
Sailaja Puttagunta officer: Chief Medical Officer C/O BIOMX LTD., 7 PINHAS SAPIR ST., FLOOR 2, NESS ZIONA L3 7414002
Brenton Karl Ahrens director 2765 SAND HILL ROAD, MENLO PARK CA 94025
Judith M. Matthews officer: Chief Financial Officer 200 WEST MONROE ST., SUITE 1575, CHICAGO IL 60606
Beth Hecht director C/O NEOS THERAPEUTICS, INC., 2940 N. HIGHWAY 360, GRAND PRAIRIE TX 75050
Alexander J Denner 10 percent owner C/O SARISSA CAPITAL MANAGEMENT LP, 660 STEAMBOAT ROAD, 3RD FLOOR, GREENWICH CT 06830
Sarissa Capital Hawkeye Fund Lp 10 percent owner 660 STEAMBOAT ROAD, 3RD FLOOR, GREENWICH CT 06830
Sarissa Capital Catapult Fund Llc 10 percent owner 660 STEAMBOAT ROAD, 3RD FLOOR, GREENWICH CT 06830
Sarissa Capital Master Fund Ii Lp 10 percent owner C/O SARISSA CAPITAL MANAGEMENT LP, 660 STEAMBOAT ROAD, 3RD FLOOR, GREENWICH CT 06830
Sarissa Capital Offshore Master Fund Lp 10 percent owner C/O SARISSA CAPITAL MANAGEMENT, 660 STEAMBOAT ROAD 3RD FLOOR, GREENWICH CT 06830
Sarissa Capital Management Lp 10 percent owner 660 STEAMBOAT ROAD, GREENWICH CT 06830
Peter Kolchinsky 10 percent owner 200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116
Ra Capital Management, L.p. 10 percent owner 200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116
Ra Capital Healthcare Fund Lp 10 percent owner 200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116